Zoladex 3.6 MG implant syrns
Ended Awarded Last action
- Contract number
- SPE2DR26FQV4S
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,156
Award facts
- Contract value 100% obligated
- $2,155.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $2,155.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Zoladex 3.6 mg implant syringes, with performance expected to conclude by February 19, 2026. The award was made on a non-set-aside, competitive basis and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a task order against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor and critical vendor for federal medical procurement needs. The company's extensive portfolio of federal contracts demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Zoladex is a hormone therapy treatment commonly used in oncology and other medical applications, reflecting the company's role in supplying specialized pharmaceutical products to support military and federal healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQV4S?
SPE2DR26FQV4S was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQV4S worth?
The government has obligated $2,156 on SPE2DR26FQV4S.
Is contract SPE2DR26FQV4S an order under another contract?
Yes. SPE2DR26FQV4S is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQV4S competed?
The extent of competition for SPE2DR26FQV4S was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award